Creative Ideas, Cutting-edge Research, and Innovative Technologies for Forward-looking Businesses
University of Massachusetts
O F F I C E O F T H E P R E S I D E N T
Commercial Ventures & Intellectual Property
A
MHERST
• B
OSTON
• D
ARTMOUTH
• L
OWELL
• W
ORCESTER
CVIP
, a University of Massachusetts initiative, turns great research into innovative technologies and moves them from laboratories to businesses ranging from start-ups to multinational corporations. CVIP-generated revenues are reinvested into the university’s growing research enterprise.
The University of Massachusetts is dedicated to transforming its discoveries into tangible benefits for our society. The results of this effort are a stronger economy, more competitive businesses, more vibrant communities, and individuals with access to better products and services.
Dvgln Rao Professor of Physics, UMass Boston Specialty: optics Craig Mello Professor of Molecular Medicine, Assistant Investigator of the Howard Hughes Medical Institute UMass Worcester Specialty: RNA interference James Watkins Associate Professor of Chemical Engineering UMass Amherst Specialty: metal deposition: SCF
CVIP
Commercial Ventures & Intellectual Property
Breathing easier Cloning for therapeutic applications
UMass Medical School innovations licensed by CVIP assisted in the development of the new anti-allergy medication Clarinex, which went on the market in 2002. UMass Amherst provided research that launched Advanced Cell Technology, Inc., one of the nation’s leading therapeutic cloning companies, licensed by CVIP.
“Innovation is one of the most important factors behind economic growth in today’s global economy. If innovation is important to the U.S. economy, it is critical to the Massachusetts economy.”
Index of the Massachusetts Innovation Economy MASSACHUSETTS T ECHNOLOGY COLLABORATIVE
Capturing the sun
UMass Lowell researchers have developed new solar-energy technology that has been incorporated in the start-up of Konarka Technologies.
Getting greener
UMass Boston researchers are making rapid advances in “green chemistry,” the effort to manufacture products with environmentally friendly processes and materials. CVIP is in discussions with two Fortune 100 companies to license renewable-energy technology and personal-care technology.
Protecting first responders
UMass Dartmouth textile engineers are working with the U.S. Army Soldier & Biological Chemical Command, Natick Soldier Center, to create garments that will protect soldiers and public safety officers from chemical and biological dangers.
Achieving nationally recognized scientific breakthroughs
UMass Medical School scientists are leaders in the important discovery of RNA interference, a novel gene-silencing technology that CVIP has licensed to more than two dozen companies.
Improving public health
The UMass Medical School’s Massachusetts Biologic Laboratories, an FDA-licensed facility, develops and manufactures human vaccines, plasma products, and monoclonal antibodies. In their unique role as a non-profit biologics manufacturer, MBL has developed important products that address critical health care concerns.
Cynthia Baldwin Professor of Veterinary and Animal Sciences UMass Amherst Specialty: cellular immunity Stephen McCarthy Professor of Plastics Engineering UMass Lowell Specialty: polymers Balram Singh Professor of Chemistry and Biochemistry UMass Dartmouth Specialty: botulism
UMass research and technology facts:
UMass received $299 million in research funding in 2002, third among Massachusetts universities and a 100 percent increase since 1996. UMass researchers have received national distinction in biology, polymers, environmental science, computer science, engineering, medicine, plastics, and other fields. Through CVIP efforts, UMass ranks among the top 20 U.S. universities in revenue from licensing university-derived technologies.
“Research at UMass has demonstrated unexpected results with commercial impact.’’ STEVE MUIR Senior Clinical Research Investigator, Pfizer, Inc. “Over the past eight years, CVIP has successfully established close relationships with a broad range of companies, from start-ups to mature corporations. CVIP has licensed technologies, facilitated research partnerships, and worked on the formation of new ventures within and outside of the UMass incubators.” BILL ROSENBERG Executive Director, CVIP “The quality of life science research at UMass is world class, rivaling that of Harvard, MIT, and WPI. It is of particular value to the Commonwealth’s medtech community.” TOM SOMMER President, MassMedic “UMass campuses…really are linchpins for creating new technologies, new jobs, and new industries in different parts of the state.” TOM HUBBARD Vice President, Massachusetts Technology Collaborative
20 16 12 8 4 0
CVIP has increased UMass licensing revenues from $500,000 in 1996 to over $20 million in 2003.
Licensing Revenue ($ millions)
’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02 ’03
200
150
CVIP has more than 140 executed licenses in effect, up from 10 in 1996.
100
Licenses in Effect
50
0
’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02 ’03
CVIP
Contact CVIP if you are: • An investor or entrepreneur building a state-of-the-art, technology-based company • A company seeking to develop innovative products • A business looking for a creative research partner
CVIP
Commercial Ventures & Intellectual Property
For more information, contact: William Rosenberg, Ph.D. Executive Director Office of the President/CVIP University of Massachusetts One Beacon Street, 26th Floor Boston, MA 02108 (617) 287-7000 wrosenberg@email.umassp.edu www.cvip-umass.net